Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.
about
Common mechanisms involved in Alzheimer's disease and type 2 diabetes: a key role of chronic bacterial infection and inflammationInflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer's DiseaseRoles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factorsPlatelets recognize brain-specific glycolipid structures, respond to neurovascular damage and promote neuroinflammationIncreased expression and local accumulation of the prion protein, Alzheimer Aβ peptides, superoxide dismutase 1, and nitric oxide synthases 1 & 2 in muscle in a rabbit model of diabetes.Feasibility of amylin imaging in pancreatic islets with β-amyloid imaging probes.Vascular and metabolic dysfunction in Alzheimer's disease: a review.Brain diabetic neurodegeneration segregates with low intrinsic aerobic capacityTherapy for Alzheimer's Disease: How Effective are Current Treatments?Integrative analysis of a cross-loci regulation network identifies App as a gene regulating insulin secretion from pancreatic islets.Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?The effect of Chinese Jinzhida recipe on the hippocampus in a rat model of diabetes-associated cognitive declineAge related changes in pancreatic beta cells: A putative extra-cerebral site of Alzheimer's pathology.Type 2 diabetes as a protein misfolding disease.Identification of Human Islet Amyloid Polypeptide as a BACE2 Substrate.Antemortem Prediction of Braak Stage.The Microtubule-Associated Protein Tau and Its Relevance for Pancreatic Beta Cells.Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics.Chronic hyperglycemia induced via the heterozygous knockout of Pdx1 worsens neuropathological lesion in an Alzheimer mouse modelToxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence?Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.Emerging roles of pathogens in Alzheimer disease.Non-cognitive symptoms and related conditions in the Alzheimer's disease: a literature review.The amyloid precursor protein: a biochemical enigma in brain development, function and disease.Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults.Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities.A Method for Diagnosing Alzheimer's Disease Based on Salivary Amyloid-β Protein 42 Levels.Human IAPP-induced pancreatic β cell toxicity and its regulation by autophagy.Molecular interaction between type 2 diabetes and Alzheimer's disease through cross-seeding of protein misfolding.Prion-Like Protein Aggregates and Type 2 Diabetes.S100A6 amyloid fibril formation is calcium-modulated and enhances superoxide dismutase-1 (SOD1) aggregation.Plasma aβ: a possible missing link between Alzheimer disease and diabetesMango leaf extract improves central pathology and cognitive impairment in a type 2 diabetes mouse model.Transactive DNA Binding Protein 43 Rather Than Other Misfolded Proteins in the Brain is Associated with Islet Amyloid Polypeptide in Pancreas in Aged Subjects with Diabetes Mellitus.Biochemical profiling of diabetes disease progression by multivariate vibrational microspectroscopy of the pancreas.The fourth element targeting hypothesis of Alzheimer's disease pathogenesis and pathophysiology.Dissecting the role of single regions of an IAPP mimic and IAPP in inhibition of Aβ40 amyloid formation and cytotoxicity.The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimer's Disease.Alzheimer's disease and type 2 diabetes: the association study of polymorphisms in tumor necrosis factor-alpha and apolipoprotein E genes.Common fibrillar spines of amyloid-β and human Islet Amyloid Polypeptide revealed by Micro Electron Diffraction and inhibitors developed using structure-based design.
P2860
Q26766681-C8AF00F3-E269-4106-B37B-4C30C70264BBQ26773657-94FBCA24-FFDF-4447-8A2A-35327BAF517DQ27022694-4965F568-F5A0-42EC-9951-16AC157D37ADQ27334497-61ADC578-6529-4066-98AC-71B960C79956Q33684979-A297C515-B370-483B-B2C7-73A707F4130EQ34072780-73F64467-B446-4C66-AB48-CFBC754DDC94Q34193337-EBB9E336-94BF-428D-B983-0A8FFC14412EQ34286417-28602D70-DEC0-4D02-931A-43FA0DA0F667Q34409349-605B88DB-7209-447E-B7CE-E9F557B706D5Q34510196-0E96E47A-0505-46C2-96ED-DDDCC7DA7375Q34608998-E89D9212-78C8-4D57-B492-C5F0B5E8510DQ34800307-75F634D9-2C5B-4EFD-8CFE-CC96A8405C05Q34878088-B99E67C8-73D3-400E-AD22-B593527841BEQ35822682-5F9539A5-8F14-452B-B6DE-B8853FC32B8BQ35913113-67982894-4B89-4208-BDC0-32A4179259F7Q36175429-CEE74BAA-F945-4B88-A829-B2501BB6A157Q36448430-1D6C73A5-5A17-4681-B2FB-4164C08E8234Q37083241-925A03D7-54E9-4204-82A2-19AFA972B60FQ37089126-F7254FC1-BBCF-49AD-AE7F-D68D336B07F8Q37698330-C0411ABA-C9C7-440E-88E0-445AD472217FQ37900307-265EC76F-F982-41AF-A2EA-1688CA68DDB9Q37935917-AD5359CD-B264-4976-8CFA-C465AEA474F2Q38094662-CFFB6C73-0FF4-4843-A610-68351FCCE54BQ38107684-2008C265-9BBE-4FD3-9295-6D9874814C03Q38603015-CBB0B1B2-D16B-4E0C-8C87-9364AE87D5E7Q38603046-8CC0680E-FBDA-4F4C-A2EC-B8AB85E2DB45Q38803093-5D6D0AB0-817D-45A8-986F-CB4F6BE4789DQ38974302-537A66CB-DADE-4B7E-B31A-E7A44B963593Q39043775-036029A7-4A1B-44F8-B602-5BB532AF826EQ39118904-384B189A-F313-4C20-831F-9BA19331E2AFQ39257498-21573E19-87E5-488D-BAF0-5CB00090668FQ39348524-7B5AB7B1-E9DE-470E-9659-3BB179D40D18Q39478082-D155AB37-564C-4336-8C14-7F971B23FABFQ40966843-74B81C13-581C-4431-9908-6940DD602E7EQ41159108-17FA8D0C-3E96-410B-AD92-72B60AA9C363Q41440925-9CCA3C4E-4881-417C-A84C-C48E4A6B5FBBQ44269390-734C2BE1-2F20-483D-A65E-901E89DB7353Q46593984-550B5B9C-7104-42CC-810C-F31ACB15624BQ46650402-D6C9FF95-5591-4AC1-ADE7-7FAD71599DA8Q47251040-3BAD42BE-4B5D-4CE1-A158-FCE584972498
P2860
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.
@ast
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.
@en
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.
@nl
type
label
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.
@ast
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.
@en
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.
@nl
prefLabel
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.
@ast
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.
@en
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.
@nl
P2093
P2860
P50
P1476
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.
@en
P2093
Aleksandra Radenovic
Bertrand Vileno
Forró Làszló
Fred Bosman
Kamel Khalili
Lisa Miller
Nune Darbinian
Patrick L McGeer
Ralph N Martins
P2860
P304
P356
10.1016/J.NEUROBIOLAGING.2008.08.019
P577
2008-10-23T00:00:00Z